Page last updated: 2024-09-05

darunavir and raltegravir potassium

darunavir has been researched along with raltegravir potassium in 101 studies

Compound Research Comparison

Studies (darunavir)	Trials (darunavir)	Recent Studies (post-2010) (darunavir)	Studies (raltegravir potassium)	Trials (raltegravir potassium)	Recent Studies (post-2010) (raltegravir potassium)
1,148	224	780	1,238	243	879

Protein Interaction Comparison

Protein	Taxonomy	darunavir (IC50)	raltegravir potassium (IC50)
Translocator protein	Rattus norvegicus (Norway rat)		0.13
Integrase	Human immunodeficiency virus 1		0.0494

Research

Studies (101)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (13.86)	29.6817
2010's	72 (71.29)	24.3611
2020's	15 (14.85)	2.80

Authors

Authors	Studies
Boffito, M; Mallon, PW; Winston, A	1
Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, PE	1
Temesgen, Z	1
Morales Conejo, M; Moreno Cuerda, VJ; Rubio García, R	1
Taéron, C	1
Barber, T; Hughes, A; Nelson, M	1
Vallone, A; Vento, S	1
Capetti, AF; Landonio, S; Perno, CF; Piconi, S; Rizzardini, G	1
Arazo Garcés, P; Omiste Sanvicente, T	1
DeLaitsch, LL; Genz, M; Klaskala, W; Lin, HY; McFarland, G; McKinnell, JA; Mrus, JM; Mugavero, MJ; Nevin, CN; Raper, JL; Saag, MS; Willig, JH	1
Arribas, JR	1
Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y	1
Aumaître, H; Blanche, S; Chaix, ML; Firtion, G; Frange, P; Rabaud, C; Reliquet, V; Tamalet, C; Thuret, I; Tricoire, J	1
Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H	1
Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M	1
Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A	1
Fujii, T; Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Miyazaki, N; Nakamura, H; Odawara, T	1
Antoniou, T; Bitnun, A; Brophy, J; Jaworsky, D; Loutfy, MR; Samson, L; Thompson, C; Yudin, MH	1
Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S	1
Bracciale, L; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Parruti, G; Prosperi, M; Ragazzoni, E	1
Cattaneo, D; Gervasoni, C	1
Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF	1
Álvarez-Tejado, M; Clotet, B; Codoñer, FM; Dalmau, D; Delgado, R; García, F; Paredes, R; Pou, C; Ruiz, L; Thielen, A	1
Corti, N; Kovari, H; Kullak-Ublick, GA; Müller, V; Taegtmeyer, AB	1
Acosta, EP; Bastow, B; Berzins, BI; Eron, JJ; Gallien, S; Kim, PS; Kuritzkes, DR; Matining, RM; Taiwo, B; Wilson, CC; Zheng, L	1
Abbas, R; Back, D; Boffito, M; Egan, D; Gazzard, B; Gedela, K; Higgs, C; Jackson, A; Khoo, S; Liptrott, N; Watson, V	1
Baldelli, S; Boreggio, G; Cattaneo, D; Clementi, E; Cozzi, V; Fucile, S; Gervasoni, C; Landonio, S; Meraviglia, P; Rizzardini, G	1
Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A	1
Abongomera, G; Back, D; Boffito, M; Dickinson, L; Gazzard, B; Gedela, K; Jackson, A; Khoo, S; Moyle, G; Taylor, J	1
de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ	1
Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P	1
Oka, S	1
Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J	1
Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C	1
Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F	1
Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G	1
Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Taburet, AM; Visseaux, B; Yazdanpanah, Y	1
Lacombe, K; Surgers, L	1
Berzins, BI; Eron, JJ; Jennings, A; Kim, PS; Kuritzkes, DR; Lederman, MM; Matining, RM; Rinaldo, CR; Taiwo, B; Wilson, CC; Zheng, L	1
De Nardo, P; Gentilotti, E; Martini, F; Narciso, P; Nicastri, E; Pucillo, LP; Tempestilli, M; Tommasi, C	1
Bicudo, EL; Cassoli, LM; da Eira, M; de Andrade Neto, JL; Furtado, J; Leite, OH; Lewi, DS; Lima, MP; Lopes, MI; Machado, AA; Madruga, JV; Miranda, AF; Netto, EM; Pedro, Rde J; Portsmouth, S; Santini-Oliveira, M; Santos, BR; Tupinambas, U; Wajsbrot, DB	1
Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E	1
Blanco, JL; Brunet, M; Calvo, M; Gatell, JM; González, A; Hidalgo, S; Laguno, M; Loncà, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Muñoz, A; Pérez, I	1
Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M	1
Guaraldi, G; Santoro, A; Stentarelli, C; Zona, S	1
Anglaret, X; Danel, C; Eholié, SP; Freedberg, KA; Losina, E; Moh, R; Ouattara, EN; Paltiel, AD; Robine, M; Ross, EL; Walensky, RP; Wong, AY; Yazdanpanah, Y	1
Aarnoutse, R; Brüggemann, R; Burger, D; Krens, S; Robijns, K; Touw, D	1
Alegre, F; Apostolova, N; Blas-García, A; Esplugues, JV; Funes, HA; Martínez, E; Polo, M	1
Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C	1
Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S	1
Imai, Y; Kawamoto, M; Kohara, N; Sekiya, H; Togo, M; Yoshimura, H	1
Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C	1
Charpentier, C; Descamps, D; Fagard, C; Harrigan, PR; Katlama, C; Lee, GQ; Molina, JM; Rodriguez, C; Storto, A; Visseaux, B; Yazdanpanah, Y	1
Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A	1
Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Motta, R; Verucchi, G; Viale, P	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, R; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO	1
Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O	1
Walter, M	1
Kato, S; Sudo, K; Takagi, R; Yamada, E	1
Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT	1
Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C	1
De Saram, S; Dhairyawan, R; Flanagan, S	1
Bloch, M; Carr, A; Lee, FJ; Mackenzie, N; Marriott, D; Richardson, R	1
Bon, I; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Re, MC; Viale, P	1
Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO	1
Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO	1
Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F	1
Estan-Cerezo, G; García-Monsalve, A; Navarro-Ruiz, A; Rodríguez-Lucena, FJ; Soriano-Irigaray, L	1
Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A	1
Fujiwara, H; Hasegawa, N; Kato, S; Takagi, R; Tanabe, Y; Yamada, E	1
Antinori, A; Bonora, S; Carbone, A; Cozzi-Lepri, A; De Luca, A; Di Biagio, A; Di Giambenedetto, S; Gianotti, N; Madeddu, G; Rusconi, S	1
Emanuel, K; Fox, HS; Lamberty, BG; Morsey, B; Stauch, KL	1
Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N	1
Ciavarella, R; Fasano, A; Latronico, T; Lichtner, M; Liuzzi, GM; Mastroianni, CM; Mengoni, F; Pati, I; Vullo, V	1
Avettand-Fenoel, V; Cheret, A; Hirt, D; Meyer, L; Morlat, P; Naqvi, A; Pressiat, C; Rouzioux, C; Tran, L; Treluyer, JM; Viard, JP; Zheng, Y	1
Blanco, J; Clotet, B; Gómez-Mora, E; Hernández-Rodríguez, A; Marfil, S; Martínez-Bonet, M; Martinez-Picado, J; Matas, L; Moltó, J; Morón-López, S; Muñoz-Fernández, MA; Puertas, MC; Santos, JR; Urrea, V	1
Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C	1
Brogan, AJ; Davis, AE; Goodwin, B	1
Tzonev, R; Yancheva, N	1
Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L	1
Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C	1
Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D	1
Anglaret, X; Anzian, A; Bado, G; Benalycherif, A; Chaix, ML; Cisse, M; Congo-Ouedraogo, M; de Monteynard, LA; Diallo, I; Diallo, M; Drabo, J; Eholie, SP; Ello, F; Gabassi, A; Gabillard, D; Girard, PM; Karcher, S; Landman, R; Le Carrou, J; Maiga, AI; Messou, E; Minta, DK; Moh, R; Peytavin, G; Sangaré, L; Sawadogo, A; Seydi, M; Toni, TD; Toure-Kane, C; Zoungrana, J	1
Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L	1
Blanco, JL; Cabello, A; Casado, JL; Deltoro, MG; Diaz De Santiago, A; Espinosa, N; Galindo, MJ; Lopez, JC; Mena, A; Montejano, R; Montero, M; Negredo, E; Palacios, R; Vergas, J; Vizcarra, P	1
Cottrell, ML; Deeks, SG; Hatano, H; Hoh, R; Hunt, PW; Kashuba, ADM; Lee, SA; Liegler, TJ; Savic, RM; Somsouk, M; Stephenson, S; Telwatte, S; Yukl, S	1
Beloumou, G; Billong, SC; Bissek, AZ; Cham, F; Colizzi, V; Dambaya, B; Elat, JN; Etame, MMN; Fokam, J; Kamgaing, N; Kamgaing, R; Mossiang, L; Moudourou, S; Moussi, EE; Nanfack, AJ; Ndjolo, A; Ngako Pamen, JN; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Temgoua, ES; Teto, G	1
Adrian, S; Beghetto, B; Erlandson, KM; Feng, H; Guaraldi, G; Lake, JE; Ligabue, G; Miao, H; Milic, J; Nardini, G; Roncaglia, E; Scherzinger, A	1
Ballivian, J; Cassetti, I; Cecchini, DM; Huberman, M; Rombini, F; Urueña, A	1
Aboura, R; Benaboud, S; Bouazza, N; Boujaafar, S; Foissac, F; Gana, I; Hirt, D; Lui, G; Treluyer, JM; Zheng, Y	1
Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL	1
Bonnet, F; Burkholder, G; Castagna, A; Cavassini, M; Cichon, P; Crane, H; Domingo, P; Gill, MJ; Grabar, S; Guest, J; Ingle, SM; Obel, N; Psichogiou, M; Rava, M; Reiss, P; Rentsch, CT; Riera, M; Sabin, CA; Schuettfort, G; Silverberg, MJ; Smith, C; Stecher, M; Sterling, TR; Sterne, JAC; Trickey, A; Zhang, L	1
Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R	1
Aebi-Popp, K; Crisinel, PA; Decosterd, L; Duppenthaler, A; Hoesli, I; Kahlert, CR; Martinez De Tejada, B; Marzolini, C; Rauch, A; Saldanha, SA	1
Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L	1
Bruzzone, B; Castagna, A; Di Biagio, A; Labate, L; Santoro, MM; Spagnuolo, V; Zazzi, M	1
Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG	1
Brites, C; Netto, EM; Patiño Escarcina, JE	1

Reviews

11 review(s) available for darunavir and raltegravir potassium

Article	Year
The clinical pharmacology of antiretrovirals in development. Expert opinion on drug metabolism & toxicology, 2006, Volume: 2, Issue:3 Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles	2006
[New therapeutic options in protracted HIV-infected patients with virological failure]. Medicina clinica, 2008, Jan-26, Volume: 130, Issue:2 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; Humans; Organic Chemicals; Peptide Fragments; Practice Guidelines as Topic; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; RNA, Viral; Sulfonamides	2008
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. The Journal of infection, 2008, Volume: 57, Issue:1 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles	2008
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 10 Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia	2008
[Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 12 Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles	2008
Hepatoxicity of new antiretrovirals: a systematic review. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2 Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles	2013
HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs, 2013, Volume: 73, Issue:13 Topics: Adiposity; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Nucleosides; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides	2013
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clinical drug investigation, 2015, Volume: 35, Issue:3 Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome	2015
Obesity science & practice, 2016, Volume: 2, Issue:1 Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult	2016
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review. The Pediatric infectious disease journal, 2017, Volume: 36, Issue:5 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load	2017
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review. Clinical pharmacokinetics, 2023, Volume: 62, Issue:9 Topics: Adenine; Adolescent; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Pharmaceutical Preparations; Raltegravir Potassium; Tenofovir; Young Adult	2023

Trials

31 trial(s) available for darunavir and raltegravir potassium

Article	Year
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Nov-01, Volume: 49, Issue:9 Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome	2009
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. International journal of STD & AIDS, 2010, Volume: 21, Issue:3 Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome	2010
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States. Journal of acquired immune deficiency syndromes (1999), 2010, Volume: 53, Issue:5 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load	2010
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antiviral therapy, 2010, Volume: 15, Issue:2 Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult	2010
Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS (London, England), 2011, Nov-13, Volume: 25, Issue:17 Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Odds Ratio; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Young Adult	2011
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals. Journal of acquired immune deficiency syndromes (1999), 2011, Dec-15, Volume: 58, Issue:5 Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Young Adult	2011
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacological research, 2012, Volume: 65, Issue:2 Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2012
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects. Antiviral therapy, 2012, Volume: 17, Issue:1 Topics: Adult; Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Darunavir; Deoxyguanine Nucleotides; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Viral Load	2012
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir	2012
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients. AIDS research and human retroviruses, 2013, Volume: 29, Issue:1 Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2013
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial). PloS one, 2013, Volume: 8, Issue:1 Topics: Anti-HIV Agents; Darunavir; DNA, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides	2013
Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study. AIDS research and human retroviruses, 2013, Volume: 29, Issue:9 Topics: Adult; Anti-HIV Agents; Brazil; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Darunavir; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maraviroc; Middle Aged; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Triazoles; Viral Load; Young Adult	2013
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial. PloS one, 2013, Volume: 8, Issue:8 Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load	2013
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors]. MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1 Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2014
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet (London, England), 2014, Nov-29, Volume: 384, Issue:9958 Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome	2014
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health. PloS one, 2014, Volume: 9, Issue:8 Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir	2014
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, 06-15, Volume: 60, Issue:12 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir	2015
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Aug-15, Volume: 61, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Darunavir; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Treatment Outcome	2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. The Journal of infectious diseases, 2015, Oct-15, Volume: 212, Issue:8 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult	2015
[In Process Citation]. MMW Fortschritte der Medizin, 2015, Volume: 157 Suppl 2 Topics: Age Factors; Aged; Comorbidity; Cross-Sectional Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Raltegravir Potassium; Tenofovir	2015
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. HIV clinical trials, 2015, Volume: 16, Issue:4 Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy	2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The lancet. HIV, 2015, Volume: 2, Issue:11 Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load	2015
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antiviral therapy, 2017, Volume: 22, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir	2017
Obesity science & practice, 2016, Volume: 2, Issue:1 Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult	2016
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. The Journal of antimicrobial chemotherapy, 2018, 04-01, Volume: 73, Issue:4 Topics: Adult; Anti-HIV Agents; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Models, Statistical; Plasma; Raltegravir Potassium; Ritonavir; Viral Load; Young Adult	2018
Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs. The Journal of antimicrobial chemotherapy, 2018, 07-01, Volume: 73, Issue:7 Topics: Adult; Antiretroviral Therapy, Highly Active; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunity, Cellular; Inflammation; Lopinavir; Lymphocyte Activation; Male; Middle Aged; Pilot Projects; Proof of Concept Study; Raltegravir Potassium; RNA, Viral; Viremia; Virus Replication	2018
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PloS one, 2018, Volume: 13, Issue:8 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States	2018
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. The lancet. HIV, 2019, Volume: 6, Issue:9 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load	2019
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial. HIV medicine, 2019, Volume: 20, Issue:10 Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir	2019
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). PloS one, 2019, Volume: 14, Issue:9 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir	2019
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001 The Journal of antimicrobial chemotherapy, 2020, 03-01, Volume: 75, Issue:3 Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load	2020

Other Studies

60 other study(ies) available for darunavir and raltegravir potassium

Article	Year
XVI International AIDS Conference: Part 2. The AIDS reader, 2006, Volume: 16, Issue:11 Topics: Acquired Immunodeficiency Syndrome; CCR5 Receptor Antagonists; Clinical Trials as Topic; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Organic Chemicals; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Ritonavir; Salvage Therapy; Sulfonamides	2006
The latest in antiretroviral therapy. Drug news & perspectives, 2006, Volume: 19, Issue:8 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles	2006
[New drugs for HIV infection]. Revue de l'infirmiere, 2008, Issue:138 Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles	2008
Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient. AIDS patient care and STDs, 2008, Volume: 22, Issue:11 Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome	2008
Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? Journal of acquired immune deficiency syndromes (1999), 2009, Feb-01, Volume: 50, Issue:2 Topics: Adult; Aged; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Sulfonamides; Treatment Outcome	2009
Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS (London, England), 2009, Jul-31, Volume: 23, Issue:12 Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load	2009
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus. AIDS (London, England), 2009, Nov-13, Volume: 23, Issue:17 Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load	2009
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:1 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load	2011
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases. Antiviral therapy, 2010, Volume: 15, Issue:4 Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Young Adult	2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients. AIDS research and human retroviruses, 2011, Volume: 27, Issue:7 Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load	2011
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacological research, 2011, Volume: 63, Issue:3 Topics: Adult; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2011
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'. AIDS (London, England), 2011, Apr-24, Volume: 25, Issue:7 Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2011
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples. Bioanalysis, 2011, Volume: 3, Issue:10 Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2011
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PloS one, 2011, Volume: 6, Issue:5 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Mutation; Pyridines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Sulfonamides; Treatment Failure	2011
Effect of continuous venovenous hemodiafiltration on darunavir and raltegravir exposure after administration via a gastroduodenal tube. AIDS (London, England), 2011, Jun-19, Volume: 25, Issue:10 Topics: Adult; Anti-Retroviral Agents; Darunavir; Hemodiafiltration; HIV Infections; Humans; Male; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome	2011
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency]. Enfermedades infecciosas y microbiologia clinica, 2012, Volume: 30, Issue:4 Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral	2012
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. Journal of acquired immune deficiency syndromes (1999), 2012, Apr-15, Volume: 59, Issue:5 Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides	2012
[Status of anti-HIV drug development and an overview of combined chemotherapy]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Nov-10, Volume: 98, Issue:11 Topics: Anti-HIV Agents; Darunavir; Drug Discovery; Drug Therapy, Combination; HIV Infections; Humans; Pyrrolidinones; Raltegravir Potassium; Sulfonamides	2009
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS pathogens, 2012, Volume: 8, Issue:6 Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia	2012
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. AIDS (London, England), 2012, Sep-10, Volume: 26, Issue:14 Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load	2012
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men. Journal of acquired immune deficiency syndromes (1999), 2013, Feb-01, Volume: 62, Issue:2 Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles	2013
Associations of T cell activation and inflammatory biomarkers with virological response to darunavir/ritonavir plus raltegravir therapy. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:8 Topics: Adult; Anti-HIV Agents; Biomarkers; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Lymphocyte Activation; Male; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; T-Lymphocytes; Viral Load	2013
Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors. International immunopharmacology, 2013, Volume: 16, Issue:4 Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4-Positive T-Lymphocytes; Cell Membrane; Cells, Cultured; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Viral; Flow Cytometry; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lymphocytes; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Rhodamine 123; Substrate Specificity; Sulfonamides; Young Adult	2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS (London, England), 2013, Apr-24, Volume: 27, Issue:7 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2013
Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients. Therapeutic drug monitoring, 2013, Volume: 35, Issue:4 Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2013
Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire. Journal of acquired immune deficiency syndromes (1999), 2014, Jul-01, Volume: 66, Issue:3 Topics: Adult; Africa South of the Sahara; Antiretroviral Therapy, Highly Active; Cost-Benefit Analysis; Darunavir; Drug Costs; Female; Health Resources; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Models, Theoretical; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Survival Analysis; Treatment Failure	2014
Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/seru Therapeutic drug monitoring, 2014, Volume: 36, Issue:6 Topics: Anti-Retroviral Agents; Clinical Laboratory Services; Darunavir; Drug Monitoring; Humans; Internationality; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Quality Control; Raltegravir Potassium; Sulfonamides	2014
Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:11 Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line, Tumor; Cells, Cultured; Cyclopropanes; Darunavir; Drug Resistance, Viral; Hepatocytes; Humans; Mitochondria; Neurons; Nitriles; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Rats; Reverse Transcriptase Inhibitors; Rilpivirine; Sulfonamides	2014
[HIV encephalopathy due to drug resistance despite 2-year suppression of HIV viremia by cART]. Rinsho shinkeigaku = Clinical neurology, 2014, Volume: 54, Issue:9 Topics: AIDS Dementia Complex; Anti-Retroviral Agents; Central Nervous System; Cognition Disorders; Darunavir; Disease Progression; Drug Resistance, Viral; Drug Substitution; HIV; HIV Infections; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viremia; Zidovudine	2014
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:7 Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Longitudinal Studies; Mutation; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load	2015
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Infectious diseases (London, England), 2015, Volume: 47, Issue:9 Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Ritonavir	2015
Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2015, Oct-10, Volume: 114 Topics: Anti-Retroviral Agents; Calibration; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Humans; Ions; Limit of Detection; Mass Spectrometry; Raltegravir Potassium; Reproducibility of Results; Saliva; Solvents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Temperature; Tenofovir	2015
Extremely high HIV-1 viral load in a patient with undiagnosed clinical indicator disease for HIV infection. BMJ case reports, 2015, Nov-24, Volume: 2015 Topics: AIDS Dementia Complex; Anti-HIV Agents; Black People; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dermatitis, Atopic; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV-1; Humans; Immunosuppressive Agents; Middle Aged; Predictive Value of Tests; Prednisolone; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load	2015
Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:4 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Hemodynamics; HIV Infections; HIV-1; Humans; Lipid Metabolism; Lipids; Raltegravir Potassium; Ritonavir; Treatment Outcome	2016
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors. HIV clinical trials, 2016, Volume: 17, Issue:1 Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load	2016
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection. Pediatric research, 2016, Volume: 80, Issue:1 Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load	2016
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. The Journal of infectious diseases, 2016, 09-01, Volume: 214, Issue:5 Topics: Adult; Anti-HIV Agents; Antigens, CD; Atazanavir Sulfate; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Male; Prospective Studies; Raltegravir Potassium; T-Lymphocyte Subsets	2016
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC infectious diseases, 2016, Aug-11, Volume: 16, Issue:1 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir	2016
A rapid validated UV-HPLC method for the simultaneous determination of the antiretroviral compounds darunavir and raltegravir in their dosage form. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2017, Volume: 30, Issue:3 Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; Darunavir; Dosage Forms; Drug Combinations; Limit of Detection; Raltegravir Potassium; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet	2017
Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients . International journal of clinical pharmacology and therapeutics, 2017, Volume: 55, Issue:7 Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protein Binding; Raltegravir Potassium; Saliva; Tandem Mass Spectrometry; Tenofovir	2017
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Infection, 2017, Volume: 45, Issue:4 Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load	2017
Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals. Journal of neurovirology, 2017, Volume: 23, Issue:6 Topics: Adenosine Triphosphate; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cerebral Cortex; Corpus Striatum; Cyclohexanes; Cyclopropanes; Darunavir; Dideoxynucleosides; Dose-Response Relationship, Drug; Emtricitabine; Lopinavir; Male; Maraviroc; Mitochondria; Neurons; Nevirapine; Oxidative Phosphorylation; Permeability; Presynaptic Terminals; Raltegravir Potassium; Rats; Rats, Long-Evans; Triazoles; Zidovudine	2017
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment. The Pediatric infectious disease journal, 2018, Volume: 37, Issue:7 Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia	2018
In vitro effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition. Journal of neurochemistry, 2018, Volume: 144, Issue:3 Topics: Animals; Anti-Retroviral Agents; Astrocytes; Cell Survival; Darunavir; Female; Male; Maraviroc; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Primary Cell Culture; Raltegravir Potassium; Rats, Wistar; Reactive Oxygen Species	2018
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1. The Journal of infectious diseases, 2018, 10-05, Volume: 218, Issue:10 Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir	2018
A case of late presentation of darunavir-related cholestatic hepatitis. International journal of STD & AIDS, 2019, Volume: 30, Issue:6 Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cholestasis, Intrahepatic; Darunavir; HIV Infections; HIV Protease Inhibitors; Homosexuality, Male; Humans; Male; Raltegravir Potassium; Treatment Outcome; Viral Load	2019
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study. The lancet. HIV, 2019, Volume: 6, Issue:11 Topics: Adult; Africa, Western; Algorithms; Clinical Decision-Making; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Raltegravir Potassium; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load	2019
Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. International journal of STD & AIDS, 2020, Volume: 31, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Coinfection; Comorbidity; Darunavir; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Retrospective Studies; Spain; Treatment Outcome; Viral Load	2020
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. Journal of acquired immune deficiency syndromes (1999), 2020, 04-15, Volume: 83, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Darunavir; Female; Gastrointestinal Tract; HIV Infections; HIV-1; Humans; Ileum; Lymph Nodes; Male; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; San Francisco; Virus Replication	2020
First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens. Antimicrobial resistance and infection control, 2020, 08-26, Volume: 9, Issue:1 Topics: Aged; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Viral Load	2020
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV. HIV research & clinical practice, 2020, Volume: 21, Issue:4 Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Italy; Male; Middle Aged; Muscles; Raltegravir Potassium; Retrospective Studies; Viral Load	2020
Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2021, Volume: 34, Issue:1 Topics: Anti-HIV Agents; Argentina; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Raltegravir Potassium; Retrospective Studies; Ritonavir; Viral Load	2021
Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2021, Mar-20, Volume: 196 Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Raltegravir Potassium; Reproducibility of Results; Tandem Mass Spectrometry; Ultrafiltration	2021
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study. Medicine, 2021, Jul-30, Volume: 100, Issue:30 Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir	2021
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The lancet. HIV, 2022, Volume: 9, Issue:6 Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Europe; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; North America; Raltegravir Potassium; Rilpivirine	2022
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States	2022
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. The Journal of antimicrobial chemotherapy, 2022, 11-28, Volume: 77, Issue:12 Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Infant; Milk, Human; Mothers; Prospective Studies; Raltegravir Potassium; Rilpivirine; Ritonavir; Switzerland	2022
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018. International journal of antimicrobial agents, 2023, Volume: 61, Issue:1 Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load	2023
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir". The new microbiologica, 2023, Volume: 46, Issue:2 Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Seropositivity; HIV-1; Humans; Raltegravir Potassium; Ritonavir; RNA; Treatment Outcome; Viral Load	2023
Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir. Medicine, 2023, Oct-06, Volume: 102, Issue:40 Topics: Adult; Anti-HIV Agents; Darunavir; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Raltegravir Potassium; Retrospective Studies; Salvage Therapy; Treatment Outcome; Viral Load	2023